Meridian Launches a New Inhibitor Tolerant qPCR Reagent to Significantly Simplify Molecular Diagnostic Workflows From Crude S...
April 18 2019 - 8:48AM
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch
of its Inhibitor-tolerant qPCR Mix, a novel mix to accelerate
workflows and improve DNA target amplification and quantification
from crude samples; adding to its growing portfolio of molecular
diagnostic products.
A variety of different inhibitors inherent to
clinical and environmental samples can negatively impact the
sensitivity and accuracy of a molecular assay. To overcome this,
specimens often have to undergo extensive processing prior to
testing. However, extraction technologies are slow and time
consuming, impacting the amount of target nucleic acid available
for testing and some enzyme inhibitors can co-elute following
purification and induce false-negative assay results.
Inhibitor-tolerant qPCR Mix contains a novel DNA
polymerase and buffer system, that is designed to reduce the amount
of sample processing required for reliable qPCR analysis and can be
used for amplification from crude lysates or inhibitor-rich samples
such as urine, saliva, cerebral spinal fluid (CSF), whole blood,
serum, plasma, feces and plants samples. This makes
Inhibitor-tolerant qPCR Mix ideally suited for applications in
cancer research, infectious disease, as well as GMO testing,
foodborne and waterborne pathogen detection.
Dr. Florent Chang-Pi-Hin, Director, Research and
Development, commented, “With the Inhibitor-tolerant qPCR Mix we
are giving our customers a highly sensitive qPCR mix for use on
crude samples. Removing the need for DNA purification not only
reduces the time to results, but also the cost of extraction, while
still allowing detection of very low copy number
targets.”
About Meridian Bioscience, Inc.Meridian is a
fully integrated life science company that develops, manufactures,
markets and distributes a broad range of innovative diagnostic
products. We are dedicated to developing and delivering better
solutions that give answers with speed, accuracy and simplicity
that are redefining the possibilities of life from discovery to
diagnosis. Through discovery and development, we provide critical
life science raw materials used in immunological and molecular
tests for human, animal, plant, and environmental applications.
Through diagnosis, we provide diagnostic solutions in areas
including gastrointestinal and upper respiratory infections and
blood lead level testing. We build relationships and provide
solutions to hospitals, reference laboratories, research centers,
veterinary testing centers, physician offices, diagnostics
manufacturers, and biotech companies in more than 70 countries
around the world.
Meridian’s shares are traded on the NASDAQ
Global Select Market, symbol VIVO. Meridian’s website address is
www.meridianbioscience.com.
Contact:Jack KennyChief Executive
OfficerMeridian Bioscience, Inc.Phone: 513.271.3700Email:
mbi@meridianbioscience.com
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Sep 2023 to Sep 2024